ECONOMIC ANALYSIS OF ETANERCEPT AS CONTINUOUS OR PAUSED THERAPY IN MODERATE TO SEVERE PSORIASIS FROM A PUBLIC PERSPECTIVE IN ARGENTINA

被引：0

作者：

Fernandes, R. A. ^{[1
]}

Takemoto, M. L. S. ^{[1
]}

Amaral, L. M. ^{[1
]}

Cruz, R. B. ^{[1
]}

Mould, J. F. ^{[2
]}

机构：

[1] ANOVA Knowledge Translat, Rio De Janeiro, RJ, Brazil

[2] Pfizer Inc, New York, NY USA

来源：

VALUE IN HEALTH | 2012年 / 15卷 / 04期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A252 / A252

页数：1

共 50 条

[21] Cost effectiveness - Analysis of Therapy with Ustekinumab versus Etanercept in Patients with moderate to severe Plaque Psoriasis Based on the ACCEPT Study
Augustin, M.
Feldman, S.
Wolbring, F.
Szapary, P.
Schenkel, B.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2011, 9 : 191 - 191
[22] Patients with moderate/severe psoriasis report overall work impairment, with improvement on etanercept therapy: results from the PRISTINE study
Augustin, M.
Remenyik, E.
Gomez Flores, M.
Kuligowski, M.
Pedersen, R.
Robertson, D.
Boggs, R.
BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (06) : E38 - E38
[23] Clinically meaningful improvements in health-related quality of life from etanercept therapy for patients with moderate to severe psoriasis
Feldman, SR
Kimball, A
Woolley, JM
Zitnik, R
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P155 - P155
[24] ANALYSIS OF THE COST PER RESPONDER OF BIOLOGICAL TREATMENTS FOR MODERATE TO SEVERE PSORIASIS IN ARGENTINA
Kanevsky, D.
Rodriguez, M. F.
Suarez Ordonez, S.
Elgart, J.
Mazzuoccolo, L. D.
VALUE IN HEALTH, 2020, 23 : S607 - S607
[25] Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis
Kress, DW
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : S126 - S128
[26] Etanercept therapy improves symptoms and allows tapering of other medications in pediatric patients with moderate to severe psoriasis
Kress, D
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P185 - P185
[27] Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis
Luger, T. A.
Barker, J.
Lambert, J.
Yang, S.
Robertson, D.
Foehl, J.
Molta, C. T.
Boggs, R.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (08) : 896 - 904
[28] Etanercept in patients with moderate to severe psoriasis who fail methotrexate: a cost-effectiveness analysis
Nallamothu, PG
Nallamothu, BK
Lim, HW
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : A63 - A63
[29] Patients with moderate to severe plaque psoriasis show improvement in patient satisfaction with etanercept therapy: a 12-week interim analysis
de Rie, M. A.
Griffiths, C. E. M.
Desris, T. A.
Robertson, D.
Freundlich, B.
Chang, D. J.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2007, 21 : 57 - 57
[30] COST-EFECTIVENESS ANALYSIS OF BIOLOGICAL AGENTS TO MODERATE TO SEVERE PLAQUE PSORIASIS TREATMENTE FROM THE BRAZILIAN PUBLIC HEALTH SYSTEM PERSPECTIVE
Senna, K.
Zimmermann, I. R.
Meirelles, I
Santos, M.
VALUE IN HEALTH, 2020, 23 : S413 - S413

← 1 2 3 4 5 →